We are live on ! Find out more
GGHC

Gilder Gagnon Howe & Co Portfolio holdings

AUM $9.69B
1-Year Est. Return 55.7%
This Fund
S&P 500
This Quarter Est. Return
+18.48%
1 Year Est. Return
+55.7%
3 Year Est. Return
+243.5%
5 Year Est. Return
+259.56%
10 Year Est. Return
+4,571.41%
AUM
$7.29B
AUM Growth
+$712M
Cap. Flow
-$287M
Cap. Flow %
-3.94%
Top 10 Hldgs %
31.93%
Holding
280
New
22
Increased
61
Reduced
163
Closed
30

Top Buys

Rank Stock Value
1
LPLA icon
LPL Financial
LPLA
+$52.3M
2
ASAN icon
Asana
ASAN
+$25.8M
3
KNF icon
Knife River
KNF
+$21.2M
4
COUR icon
Coursera
COUR
+$21M
5
MNDY icon
monday.com
MNDY
+$16.8M

Sector Composition

Rank Sector Weight
1 Technology 34.33%
2 Consumer Discretionary 19.26%
3 Healthcare 14.28%
4 Communication Services 12.26%
5 Industrials 8.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FLG
276
Flagstar Bank National Association
FLG
$5.4B
-195,652
Closed -$6.66M
NARI
277
DELISTED
Inari Medical, Inc. Common Stock
NARI
-51,931
Closed -$3.4M
NVTA
278
DELISTED
Invitae Corporation
NVTA
-99,813
Closed -$60.4K
DEN
279
DELISTED
Denbury Inc.
DEN
-119,754
Closed -$11.7M
ATVI
280
DELISTED
Activision Blizzard
ATVI
-18,922
Closed -$1.77M

Similar funds

Gilder Gagnon Howe & Co's Q4 2023 Portfolio in Review

As of Q4 2023, Gilder Gagnon Howe & Co held 280 positions worth $7.29B, up 11% from $6.57B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Gilder Gagnon Howe & Co withdrew a net $287M in Q4 2023, closing 30 positions and reducing 163 holdings. Its most notable exit was Amylyx Pharmaceuticals, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 33% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Gilder Gagnon Howe & Co opened a new position in Asana worth $25.2M.

  • Gilder Gagnon Howe & Co's largest Q4 2023 buy was Asana: 1,328,019 shares worth $25.2M.
  • Gilder Gagnon Howe & Co added most to LPL Financial in Q4 2023, an estimated $52.3M increase.
  • Gilder Gagnon Howe & Co's biggest Q4 2023 reduction was Canadian Pacific Kansas City, cutting an estimated $82M.
  • Gilder Gagnon Howe & Co fully exited Amylyx Pharmaceuticals in Q4 2023, selling an estimated $12.6M.
  • Gilder Gagnon Howe & Co's ten largest holdings make up 32% of its $7.29B portfolio in Q4 2023.
  • Gilder Gagnon Howe & Co opened 22 new positions and closed 30 in Q4 2023.
  • Gilder Gagnon Howe & Co's portfolio value rose 11% quarter-over-quarter to $7.29B.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2023, filed 14 Feb 2024.